Abstract
Purpose Although cardiorespiratory fitness (CRF) is inversely associated with breast cancer risk, whether CRF modifies the association between breast cancer polygenic risk score (PRS) and incident breast cancer remains unclear. We examined the independent and joint associations of CRF and breast cancer PRS with incident breast cancer in postmenopausal women from the UK Biobank and evaluated multiplicative and additive interactions between CRF and breast cancer PRS.
Methods This prospective cohort study included postmenopausal women from the UK Biobank. CRF was estimated using a submaximal cycle ergometer test, and genetic susceptibility was assessed using a breast cancer PRS. Cox proportional hazards models adjusted for established breast cancer risk factors were used to estimate hazard ratios. Multiplicative and additive interactions between CRF and PRS were evaluated, with additive interaction assessed using the relative excess risk due to interaction (RERI).
Results Among 15,199 postmenopausal women, 547 women developed incident breast cancer during a median follow-up of 10.7 years. Higher CRF was associated with lower risk of incident breast cancer in a dose–response manner, whereas higher PRS was associated with higher risk. Although multiplicative interaction was not significant, additive interaction analyses indicated that higher CRF was associated with attenuation of excess breast cancer risk conferred by high PRS (RERI −0.79, 95% CI −1.47 to −0.10). This attenuation was particularly evident among women aged ≥60 years.
Conclusions Higher CRF was associated with lower breast cancer risk and attenuation of excess breast cancer risk conferred by elevated polygenic risk, particularly among older women. These findings support the potential role of CRF in risk-stratified breast cancer prevention strategies.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted using the UK Biobank Resource under application number 185057. UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (REC reference: 11/NW/0382), and all participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version has been revised following peer review. We reconsidered the exclusion of women with a history of hysterectomy and retained those whose postmenopausal status could be established based on natural menopause or bilateral oophorectomy. Consequently, the analytic sample increased from 13,907 to 15,199 women, and the number of incident breast cancer cases increased from 500 to 547. All analyses were repeated using the revised analytic sample. We also revised the handling of age at menopause, performed additional Fine-Gray competing-risk analyses treating all-cause death before breast cancer diagnosis as a competing event, and updated the corresponding figures, tables, and Supplemental Digital Content. The main findings and conclusions were not materially altered.
Data Availability
The data used in this study are available from the UK Biobank under application number 185057. Researchers can apply for access to the UK Biobank resource through the UK Biobank Access Management System (https://www.ukbiobank.ac.uk/).
https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access
Funder Information Declared
